Judy

Medical device engineers use Design for Manufacturing (DFM) to lower procurement costs by selecting cost-effective, biocompatible materials and standardizing components, reducing custom parts by up to 30% while maintaining clinical efficacy through rigorous testing and regulatory compliance. Check: Bio Medical Procurement Strategy: Balancing Innovation with Budgetary Constraints What Is Design for Manufacturing (DFM) in Medical […]

Sourcing medical devices from Korea and Japan in 2026 is being reshaped by two major regulatory shifts: Korea’s MFDS “negative list” system for device changes and Japan’s PMDA‑direct pathway for specific‑use designations. These reforms can shorten certain timelines for Tier‑1 manufacturers in Seoul and Tokyo, but they also raise the bar for documentation, quality systems,

Innovative medical devices for De Quervain syndrome and tendonitis have evolved from static splints to dynamic recovery hardware like ergonomic braces and 3D-printed orthotics. These offload the abductor pollicis longus tendon by stabilizing the thumb and wrist, reducing friction in the first dorsal compartment for faster healing. Check: Bio Medical Procurement Strategy: Balancing Innovation with

China’s NMPA released over 80 new industry standards in February 2026 and revised GMP effective November 2026, enhancing quality management across device lifecycles. Class 1 devices face lighter immediate impacts via filings, while higher-risk classes require stricter registrant oversight and audits. International manufacturers must align QMS with these updates for continued market access. Check: Bio

The 2026 EU MDR marketing checklist requires all claims in medical device promotions to match the device’s intended purpose, backed by clinical evidence, while following Article 7 and national laws. Marketing materials like websites and brochures must avoid misleading info and undergo regulatory review. HHG GROUP supports MedTech firms through compliant trading platforms. Check: How

Navigating Japan’s PMDA and Korea’s MFDS requires understanding distinct regulatory pathways: Japan uses PMD Act classifications (Class I-IV) with MAH/DMAH requirements and PMDA review, targeting 12-month approvals; Korea’s MFDS employs four risk-based classes needing notification, certification, or approval. A modern procurement strategy aligns submissions early, leverages local representatives, and monitors harmonization to cut import delays

Medical devices sales in 2026 are shifting from relationship-driven approaches to data-centric strategies powered by analytics, digital platforms, and procurement alignment. Sales teams now focus on measurable outcomes, faster deal cycles, and seamless integration with hospital systems. Success depends on optimizing workflows, improving transparency, and leveraging platforms like HHG GROUP to connect with buyers efficiently

Healthcare procurement can significantly improve patient outcomes in postural orthostatic tachycardia syndrome (POTS) and broader dysautonomia care when it moves beyond cost reduction and instead focuses on sourcing specialized devices that enhance symptom control, functional capacity, and long‑term stability. By aligning purchasing decisions with clinical goals, quality‑of‑life measures, and readmission risk, organizations can deliver better

Automation in medical device assembly is transforming how MedTech manufacturers achieve near‑zero defect rates. By integrating AI, robotics, and sensor‑driven “smart factories,” companies can standardize assembly, detect anomalies in real time, and maintain continuous process improvement. For procurement teams, this means auditing a manufacturer’s assembly automation is now a prerequisite for long‑term, zero‑defect sourcing strategies.

Medical device shortages in 2026—especially in products like stereotactic breast biopsy needles and dialysis bloodlines—are expected to persist into Q4, disrupting surgical schedules and dialysis care. By diversifying vendors, monitoring the FDA medical device shortage list, and leveraging digital‑first procurement platforms such as HHG GROUP, health systems can build supply‑chain resilience and reduce OR‑level disruptions.